Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Maternal and Infant Immunization Strategies to Prevent Pneumococcal Disease
Brief Summary: This prospective randomized evaluation of pneumococcal vaccine immunization of pregnant mothers, followed by pneumococcal conjugate immunization of their children is designed to assess the effects of these strategies on the immunogenicity and safety of both vaccines. We hypothesize that maternal followed by infant immunization will be safe and will provide higher levels of antibody from birth through 12 months of age.


Options:
A: Intervention Type: BIOLOGICAL; Name: pneumococcal polysaccharide and protein conjugate vaccines; Assigned to Arm(s): N/A
B: Arm Label: split-virion, non-adjuvanted H1N1 vaccine of 15 μg; Type: EXPERIMENTAL; Interventions: Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg | Intervention Type: BIOLOGICAL; Name: split-virion, non-adjuvanted H1N1 vaccine of 15 μg; Assigned to Arm(s): split-virion, non-adjuvanted H1N1 vaccine of 15 μg
C: Arm Label: VAX128; Type: EXPERIMENTAL; Interventions: Biological: VAX128 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: VAX128; Assigned to Arm(s): VAX128 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GSK1562902A non-AD F1 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F2 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F3 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F4 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A AD F1 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD F2 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD F3 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD Approved F4 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: Control Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Intervention Type: BIOLOGICAL; Name: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose; Assigned to Arm(s): GSK1562902A AD Approved F4 Primed Group, GSK1562902A AD F1 Primed Group, GSK1562902A AD F2 Primed Group, GSK1562902A AD F3 Primed Group | Intervention Type: BIOLOGICAL; Name: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses; Assigned to Arm(s): Control Group, GSK1562902A non-AD F1 Primed Group, GSK1562902A non-AD F2 Primed Group, GSK1562902A non-AD F3 Primed Group, GSK1562902A non-AD F4 Primed Group

Answer: A